Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On May18, 2017, Recro Pharma, Inc. (the Company) announced that
it will present a poster presentation entitled Efficacy and
Safety of N1539, Intravenous Meloxicam, in a Phase 3 Study of
Subjects with Moderate to Severe Pain following Bunionectomy at
the American Pain Society 36th Annual Scientific Meeting, taking
place May 17-20, 2017, in Pittsburgh, PA. A copy of the press
release announcing the poster presentation and a copy of the
poster presentation are furnished herewith as Exhibits 99.1 and
99.2, respectively. A copy of the poster presentation will also
be made available on the Companys website.
The information disclosed under Item 7.01, including Exhibits
99.1 and 99.2, is being furnished and shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, and shall not be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Document |
|
| 99.1 | Press release of Recro Pharma, Inc., dated May18, 2017. | |
| 99.2 |
Poster of Recro Pharma, Inc. entitled Efficacy and Safety of N1539, Intravenous Meloxicam, in a Phase 3 Study of Subjects with Moderate to Severe Pain following Bunionectomy. |
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. Recro Pharma, Inc. (NASDAQ:REPH) Recent Trading Information
Recro Pharma, Inc. (NASDAQ:REPH) closed its last trading session down -0.13 at 8.35 with 384,440 shares trading hands.